Dr. Sewanti Limaye, MD, MS
Director of Precision Oncology Director of Clinical and Translational Oncology Research Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute Translational Research Institute (TRI) Mumbai, India
Dr. Sewanti Limaye, MD, MSDirector of Precision OncologyDirector of Clinical and Translational Oncology ResearchKokilaben Dhirubhai Ambani Hospital and Medical Research InstituteTranslational Research Institute (TRI) Mumbai, India
Dr. Sewanti Limaye is a career Precision Oncologist and serves as the Director of Precision Oncology and Director of Clinical and Translational Research at Kokilaben Dhirubhai Ambani Hospital and Medical Research Center in Mumbai, India. Before moving to India, she served as a faculty at the Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA, and at Columbia University Medical Center/New York Presbyterian Hospital, New York, USA. She is the first amongst the Indian medical oncologists to set up a Precision Oncology Clinic in India.
Dr. Limaye received her medical degree with honors from Jawahar Lal Nehru Medical College. She completed her residency in Internal Medicine at New York University. Later, she completed her fellowship in Hematology and Medical Oncology from Albert Einstein University, New York. She obtained Masters in Patient Oriented Research (Cancer Genomics and Biostatistics) from Mailman School of Public Health, Columbia University, NY.
Dr. Limaye was awarded numerous awards including the John-Flynn Young Investigator Award for Excellence in Clinical Research; the Rose and Jack Horowitz Award for Excellence in Patient Care; Medical Oncology Research Excellence Award-ASCO 2008 for Excellence in Clinical Research. She was nominated to serve as the National Chair of the Sub-protocol Arm B of the landmark NCI-MATCH Trial. Dr. Limaye is a results-oriented oncologist and a lifetime cancer researcher and clinician investigator. She is committed to novel drug development and to delivering evidence-based and cutting-edge treatment for cancer patients.
“There is no other way of practicing oncology other than Precision Oncology. Besides, we are at the crossroads of understanding the tumor at Molecular-level and efficiently identifying the vulnerabilities through genome sequencing. These vulnerabilities will allow us to treat and cure cancer using a novel evidence-based effective combination of therapies.”